Healthcare Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 329,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "508d4a9e-9ef8-4bf1-9904-e18682193253",
"title": "ResMed Inc's Meteoric Rise: Unpacking the 12% Surge in Just 3 Months",
"description": "ResMed Inc (RMD) has experienced a significant uptick in its stock performance, with a market capitalization now standing at $31.48 billion. The current price o",
"keywords": "GuruFocus, Article, News, GuruFocus Research, RMD, WST, BAX, COO",
"snippet": "ResMed Inc (RMD, Financial) has experienced a significant uptick in its stock performance, with a market capitalization now standing at $31.48 billion. The curr...",
"url": "https://www.gurufocus.com/news/2419758/resmed-incs-meteoric-rise-unpacking-the-12-surge-in-just-3-months",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-04-26T16:16:43.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "RSMDF",
"name": "ResMed Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 54.146935,
"sentiment_score": 0.7078,
"highlights": [
{
"highlight": "<em>ResMed</em> <em>Inc</em> (RMD, Financial) has experienced a significant uptick in its stock performance, with a market capitalization now standing at $31.48 billion. The current price of $214.04 reflects an impressive 18.99% gain over the past week and a 12.20% gain over the past three months.",
"sentiment": 0.8979,
"highlighted_in": "main_text"
},
{
"highlight": "Introducing <em>ResMed</em> <em>Inc</em>\n\n<em>ResMed</em> <em>Inc</em>, a leader in the medical devices and instruments industry, specializes in respiratory care devices. The company's focus on sleep apnea treatment, combined with an aging population and rising obesity rates, positions it in a growing market.",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "With a significant presence in the Americas and a strong footprint in Europe, Japan, and Australia, <em>ResMed</em> is expanding its reach. The company's strategic emphasis on digital health through acquisitions and development underscores its commitment to innovation.",
"sentiment": 0.8555,
"highlighted_in": "main_text"
},
{
"highlight": "Baillie Gifford (Trades, Portfolio)'s stake of 60,046 shares makes up 0.04% of <em>ResMed</em>, showcasing the confidence these seasoned investors have in the company's prospects.\n\nCompetitive Landscape\n\nIn comparison to its peers, <em>ResMed</em> holds a strong position in the market.",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Conclusion\n\nIn summary, <em>ResMed</em> Inc's recent stock performance, with a 12.20% gain over the past three months, is a testament to its strong financial health and growth potential. The company's strategic focus on digital health, combined with its impressive profitability and growth metrics, positions it favorably against competitors.",
"sentiment": 0.9578,
"highlighted_in": "main_text"
},
{
"highlight": "With the backing of notable investors and a market-leading position, <em>ResMed</em> is well-equipped to continue its trajectory of success in the dynamic medical devices sector.\n\nThis article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice.",
"sentiment": 0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ResMed</em> Inc's Meteoric Rise: Unpacking the 12% Surge in Just 3 Months",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "ee23681e-6068-4d52-9115-f458af22450f",
"title": "Full Year 2024 Daiichi Sankyo Co Ltd Earnings Presentation Transcript",
"description": "Apr 25, 2024 / 06:00AM GMTPresentationApr 25, 2024 / 06:00AM GMT =====================Corporate Participants===================== * Hiroyuki Okuzawa Dai",
"keywords": "GuruFocus, Article, News, GuruFocus Research, OTCPK:DSKYF",
"snippet": "Apr 25, 2024 / 06:00AM GMT\n\nPresentation\n\nApr 25, 2024 / 06:00AM GMT\n\n\n\n=====================\n\nCorporate Participants\n\n=====================\n\n* Hiroyuki Okuzawa...",
"url": "https://www.gurufocus.com/news/2419754/full-year-2024-daiichi-sankyo-co-ltd-earnings-presentation-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-04-26T16:08:53.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "4568.T",
"name": "Daiichi Sankyo Company, Limited",
"exchange": null,
"exchange_long": null,
"country": "jp",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.46094,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Apr 25, 2024 / 06:00AM GMT\n\nPresentation\n\nApr 25, 2024 / 06:00AM GMT\n\n\n\n=====================\n\nCorporate Participants\n\n=====================\n\n* Hiroyuki Okuzawa\n\n<em>Daiichi</em> <em>Sankyo</em> <em>Company</em>, <em>Limited</em> - President, COO & Representative Director\n\n* Ken Takeshita\n\n<em>Daiichi</em> <em>Sankyo</em> <em>Company</em>, <em>Limited</em> - Head of Research & Development Unit\n\n* Koji Ogawa\n\n<em>Daiichi</em> <em>Sankyo</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Company</em>, <em>Limited</em> - Managing Executive Officer, Head of Global Corporate Planning & Management and CFO\n\n\n\n=====================\n\nConference Call Participants\n\n=====================\n\n* Hidemaru Yamaguchi\n\nCitigroup Global Markets Japan Inc., Research Division - MD, Analyst & Head of Pan-Asia Healthcare Sector\n\n* Kasumi Haruta\n\nUBS Investment Bank, Research",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DSNKY",
"name": "Daiichi Sankyo Company, Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.45004,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Apr 25, 2024 / 06:00AM GMT\n\nPresentation\n\nApr 25, 2024 / 06:00AM GMT\n\n\n\n=====================\n\nCorporate Participants\n\n=====================\n\n* Hiroyuki Okuzawa\n\n<em>Daiichi</em> <em>Sankyo</em> <em>Company</em>, <em>Limited</em> - President, COO & Representative Director\n\n* Ken Takeshita\n\n<em>Daiichi</em> <em>Sankyo</em> <em>Company</em>, <em>Limited</em> - Head of Research & Development Unit\n\n* Koji Ogawa\n\n<em>Daiichi</em> <em>Sankyo</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Company</em>, <em>Limited</em> - Managing Executive Officer, Head of Global Corporate Planning & Management and CFO\n\n\n\n=====================\n\nConference Call Participants\n\n=====================\n\n* Hidemaru Yamaguchi\n\nCitigroup Global Markets Japan Inc., Research Division - MD, Analyst & Head of Pan-Asia Healthcare Sector\n\n* Kasumi Haruta\n\nUBS Investment Bank, Research",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DSKYF",
"name": "Daiichi Sankyo Company, Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.4483,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Apr 25, 2024 / 06:00AM GMT\n\nPresentation\n\nApr 25, 2024 / 06:00AM GMT\n\n\n\n=====================\n\nCorporate Participants\n\n=====================\n\n* Hiroyuki Okuzawa\n\n<em>Daiichi</em> <em>Sankyo</em> <em>Company</em>, <em>Limited</em> - President, COO & Representative Director\n\n* Ken Takeshita\n\n<em>Daiichi</em> <em>Sankyo</em> <em>Company</em>, <em>Limited</em> - Head of Research & Development Unit\n\n* Koji Ogawa\n\n<em>Daiichi</em> <em>Sankyo</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Company</em>, <em>Limited</em> - Managing Executive Officer, Head of Global Corporate Planning & Management and CFO\n\n\n\n=====================\n\nConference Call Participants\n\n=====================\n\n* Hidemaru Yamaguchi\n\nCitigroup Global Markets Japan Inc., Research Division - MD, Analyst & Head of Pan-Asia Healthcare Sector\n\n* Kasumi Haruta\n\nUBS Investment Bank, Research",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "2e6c0abd-ace9-4eb3-a18e-8dd8453694a6",
"title": "AbbVie's Q1: Positive Surprise (NYSE:ABBV)",
"description": "AbbVie's earnings beat estimates, with a smaller decline in Humira sales. Read how the biotech's next-generation drugs Rinvoq and Skyrizi are offsetting a decline in Humira sales.",
"keywords": "",
"snippet": "vzphotos\n\nArticle Thesis\n\nAbbVie Inc. (NYSE:ABBV) reported its first quarter earnings results Friday morning. The company's results beat estimates on both lines...",
"url": "https://seekingalpha.com/article/4686695-abbvie-q1-positive-surprise",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-04-26T16:01:50.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "4AB.DE",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 27.150555,
"sentiment_score": 0.47204,
"highlights": [
{
"highlight": "vzphotos\n\nArticle Thesis\n\n<em>AbbVie</em> <em>Inc</em>. (NYSE:ABBV) reported its first quarter earnings results Friday morning. The company's results beat estimates on both lines as the Humira sales decline was less pronounced than feared.",
"sentiment": -0.4417,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AbbVie</em> reported its Q1 earnings results on Friday morning before the market opened. The headline results can be seen in the following screencap:\n\n<em>AbbVie</em> results (Seeking Alpha)\n\nWe see that <em>AbbVie</em> <em>Inc</em>. was able to outperform analyst expectations for both its top line and its bottom line, which naturally was a positive surprise.",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "Analysts tend to underestimate <em>AbbVie</em>, with the company now having beaten profit estimates in 18 out of the last 20 quarters.\n\n<em>AbbVie</em>: Underlying Performance Is Solid\n\nAs noted earlier, the loss of Humira's patent protection in the US last year was a headwind for the company.",
"sentiment": -0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "But while a range of competitors has come to the market with their respective biosimilars, <em>AbbVie</em> has managed to hold a better-than-expected market share in its home market. Seeking Alpha reported earlier this month that <em>AbbVie</em> had retained a market share of close to 100%, although this was only possible due to some pricing concessions.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "When it comes to profits, <em>AbbVie</em> beat estimates, but results were down vs. the previous year's quarter nevertheless. Adjusted earnings per share were down by a little more than 6%, which isn't disastrous, but not great.",
"sentiment": 0.5664,
"highlighted_in": "main_text"
},
{
"highlight": "The better-than-expected Humira performance in the United States helps explain why <em>AbbVie</em> believes it will be more profitable than previously thought.",
"sentiment": 0.8207,
"highlighted_in": "main_text"
},
{
"highlight": "On the other hand, investors should not disregard the fact that the updated guidance still implies that profitability will be significantly weaker than during the peak years 2021 and 2022 when <em>AbbVie</em> was earning well above $12 per share.\n\nIs <em>AbbVie</em> A Good Investment?\n\n<em>AbbVie</em> is a quality company, I believe.",
"sentiment": 0.8369,
"highlighted_in": "main_text"
},
{
"highlight": "Profits declined during the first quarter, which suggests that <em>AbbVie</em> should not be trading at a high valuation.\n\nWith peers such as Pfizer Inc. (PFE) or Roche Holding AG (OTCQX:RHHBY) trading at just 11x to 12x net profits, <em>AbbVie</em> looks somewhat pricey on a relative basis.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "For many investors, <em>AbbVie</em> is a dividend growth investment primarily thanks to its compelling dividend growth track record.",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "When we consider that <em>AbbVie</em> traded at as low as $131 over the last year, the current share price of more than $160 is not overly compelling. I thus consider <em>AbbVie</em> a \"Hold\"/\"Neutral\" right now.\n\nEditor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE.DE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.40921,
"sentiment_score": 0.8979,
"highlights": [
{
"highlight": "With peers such as <em>Pfizer</em> <em>Inc</em>. (PFE) or Roche Holding AG (OTCQX:RHHBY) trading at just 11x to 12x net profits, AbbVie looks somewhat pricey on a relative basis.\n\nFor many investors, AbbVie is a dividend growth investment primarily thanks to its compelling dividend growth track record.",
"sentiment": 0.8979,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVS.DE",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.225437,
"sentiment_score": -0.0164,
"highlights": [
{
"highlight": "That being said, it's possible that the Humira sales decline will be more severe in the upcoming quarters due to the fact that <em>CVS</em> <em>Health</em> <em>Corporation</em> (CVS) is now favoring the biosimilars from AbbVie's competitors - we will see how that impacts AbbVie's results when the company announces its second-quarter earnings around three months from now.",
"sentiment": -0.0164,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "59f18af8-4e74-4e3f-8fa7-425fba84884c",
"title": "Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy (NYSE:NVO)",
"description": "Novo Nordisk's weight loss drug, Wegovy, receives FDA approval for reducing cardiovascular risk, potentially leading to significant revenue growth. Learn more on NVO stock here.",
"keywords": "",
"snippet": "aprott\n\nNovo Nordisk A/S (NVO) secured the FDA approval for Wegovy, the weight loss version of the compound called semaglutide, for the indication of reducing r...",
"url": "https://seekingalpha.com/article/4686716-novo-nordisk-medicare-coverage-unlock-another-big-market-wegovy",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2025836701/image_2025836701.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-04-26T16:00:34.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVC.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.110855,
"sentiment_score": -0.0258,
"highlights": [
{
"highlight": "aprott\n\n<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> (NVO) secured the FDA approval for Wegovy, the weight loss version of the compound called semaglutide, for the indication of reducing risks of major cardiovascular adverse events ('MACE') in early March.",
"sentiment": -0.0258,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.DE",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.854805,
"sentiment_score": -0.4641,
"highlights": [
{
"highlight": "The MACE (heart health) label expansion not only makes Wegovy more attractive for overweight and obese patients wanting to lose weight, it further extends Novo Nordisk's leadership position in the obesity market as no competitor other than <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em> (LLY) will have such a broad label anytime soon.",
"sentiment": -0.4641,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.11042,
"sentiment_score": -0.0258,
"highlights": [
{
"highlight": "aprott\n\n<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> (NVO) secured the FDA approval for Wegovy, the weight loss version of the compound called semaglutide, for the indication of reducing risks of major cardiovascular adverse events ('MACE') in early March.",
"sentiment": -0.0258,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "8b0e4889-dc37-45e9-852e-433b38d52b8c",
"title": "AstraZeneca: Strong In A Weak Market (NASDAQ:AZN)",
"description": "Shares of AstraZeneca reached new all-time highs this week despite difficult market conditions in the last two months. Learn more on AZN stock here.",
"keywords": "",
"snippet": "Wirestock\n\nShares of AstraZeneca PLC (NASDAQ:AZN) have reached new all-time highs this week thanks to a strong first quarter earnings report. The situation has ...",
"url": "https://seekingalpha.com/article/4686685-astrazeneca-strong-in-a-weak-market",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1437627078/image_1437627078.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-04-26T15:33:56.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 42.501747,
"sentiment_score": 0.655564,
"highlights": [
{
"highlight": "Wirestock\n\nShares of <em>AstraZeneca</em> <em>PLC</em> (NASDAQ:AZN) have reached new all-time highs this week thanks to a strong first quarter earnings report.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "And whether the upside potential can be better than I am envisioning likely depends on how successful <em>AstraZeneca</em> is in getting a stronger foothold into an increasingly attractive but also increasingly competitive obesity market.",
"sentiment": 0.7992,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> Q1 2024 earnings presentation\n\nThe outperformance of the oncology division was driven by the strong growth of some key products such as Imfinzi, Calquence, and Enhertu with 33%, 35%, and 79% Y/Y growth, respectively, in the first quarter.",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> claims continued leadership in the first-line chronic lymphocytic leukemia ('CLL') market, but looking a bit further behind that statement, we can see the emerging BTK inhibitor, BeiGene, Ltd.'",
"sentiment": -0.1154,
"highlighted_in": "main_text"
},
{
"highlight": "Calquence does not have that as it has only managed to show non-inferiority on efficacy compared to Imbruvica, but with a safety edge which <em>AstraZeneca</em> has used to its advantage since launch. Even so, I expect both Calquence and Brukinsa to do well and to continue to take market share from Imbruvica in the following years.",
"sentiment": 0.8922,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em>, AbbVie, J&J, BeiGene earnings reports, author's estimates for Q1 2024 market share of Imbruvica and Brukinsa\n\nThe growth of the cardiovascular, renal, and metabolic ('CVRM') segment was driven by the 45% Y/Y growth of Farxiga, and the growth of the respiratory and immunology ('R&I') segment was driven by the strong uptake of Tezspire with",
"sentiment": 0.9062,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> Q1 earnings report presentation\n\nHowever, I am most interested in seeing updates and potential company actions on the obesity side of the pipeline as I believe it holds the key to more significant value creation.",
"sentiment": 0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "However, <em>AstraZeneca</em> still has a lot to prove and is well behind the market leaders Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY).\n\nI wrote briefly about how <em>AstraZeneca</em> is approaching the obesity market in my late 2023 article, but I will slightly expand today.",
"sentiment": 0.4774,
"highlighted_in": "main_text"
},
{
"highlight": "Conclusion\n\n2024 is off to a strong start for <em>AstraZeneca</em> with a strong revenue beat and 19% Y/Y growth in the first quarter.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "And even though the full-year guidance was not changed from the low-double digit top and bottom line growth compared to 2023, the performance of all key products and the recent and potential pipeline wins put <em>AstraZeneca</em> in a good position to continue to outperform expectations throughout 2024 and beyond.",
"sentiment": 0.875,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em>: Strong In A Weak Market (NASDAQ:AZN)",
"sentiment": 0.1027,
"highlighted_in": "title"
}
]
},
{
"symbol": "NOVC.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 20.640614,
"sentiment_score": 0.4774,
"highlights": [
{
"highlight": "However, AstraZeneca still has a lot to prove and is well behind the market leaders <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> (NVO) and Eli Lilly and Company (LLY).\n\nI wrote briefly about how AstraZeneca is approaching the obesity market in my late 2023 article, but I will slightly expand today.",
"sentiment": 0.4774,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.DE",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 21.332752,
"sentiment_score": 0.4774,
"highlights": [
{
"highlight": "However, AstraZeneca still has a lot to prove and is well behind the market leaders Novo Nordisk A/S (NVO) and <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em> (LLY).\n\nI wrote briefly about how AstraZeneca is approaching the obesity market in my late 2023 article, but I will slightly expand today.",
"sentiment": 0.4774,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 20.640213,
"sentiment_score": 0.4774,
"highlights": [
{
"highlight": "However, AstraZeneca still has a lot to prove and is well behind the market leaders <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> (NVO) and Eli Lilly and Company (LLY).\n\nI wrote briefly about how AstraZeneca is approaching the obesity market in my late 2023 article, but I will slightly expand today.",
"sentiment": 0.4774,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "c2999171-d95b-485b-ba28-f27bdcdd5aac",
"title": "Drug Delivery Technologies market is projected to grow at a CAGR of 5.5% by 2034: Visiongain",
"description": "Visiongain has published a new report entitled Drug Delivery Technologies Market Report 2024-2034: Forecasts by Route of Administration (Implantable Drug...",
"keywords": "Visiongain Reports Ltd, Drug delivery technologies, pharma industry growth, pharma industry research, Pharma Market Report, Visiongain Pharma Reports",
"snippet": "Visiongain has published a new report entitled Drug Delivery Technologies Market Report 2024-2034: Forecasts by Route of Administration (Implantable Drug Delive...",
"url": "https://www.globenewswire.com/news-release/2024/04/26/2870540/0/en/Drug-Delivery-Technologies-market-is-projected-to-grow-at-a-CAGR-of-5-5-by-2034-Visiongain.html",
"image_url": "https://ml-eu.globenewswire.com/Resource/Download/6bdb779b-409b-453a-a1ac-5548f5b2a98e",
"language": "en",
"published_at": "2024-04-26T13:15:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.030336,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Boehringer Ingelheim, <em>AstraZeneca</em> <em>plc</em>, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMGN",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.168067,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Sanofi, <em>Amgen</em> <em>Inc</em>., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.027685,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ABBV",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.035943,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>AbbVie</em> <em>Inc</em>., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.818892,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Boehringer Ingelheim, AstraZeneca plc, <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVS",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.579927,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Novartis</em> <em>AG</em>, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BSX",
"name": "Boston Scientific Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.008333,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Bristol-Myers Squibb, Gerresheimer AG, <em>Boston</em> <em>Scientific</em> <em>Corporation</em>. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BSX-PA",
"name": "Boston Scientific Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.008345,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Bristol-Myers Squibb, Gerresheimer AG, <em>Boston</em> <em>Scientific</em> <em>Corporation</em>. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.929069,
"sentiment_score": 0.3548,
"highlights": [
{
"highlight": "., Bayer AG, BD, GSK plc, <em>Merck</em> & <em>Co</em>., <em>Inc</em>., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On 20th September 2023, <em>Merck</em> announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.924777,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Pfizer</em> <em>Inc</em>., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 8.924777,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Pfizer</em> <em>Inc</em>., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.985405,
"sentiment_score": 0.1779,
"highlights": [
{
"highlight": "Competitive Landscape\n\nThe major players operating in the drug delivery technologies market are <em>Johnson</em> & <em>Johnson</em> Services, Inc., Novartis AG, F.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.029941,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Boehringer Ingelheim, <em>AstraZeneca</em> <em>plc</em>, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVSEF",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.579789,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Novartis</em> <em>AG</em>, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GRRMF",
"name": "Gerresheimer AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 14.322987,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Bristol-Myers Squibb, <em>Gerresheimer</em> <em>AG</em>, Boston Scientific Corporation. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NOVN.SW",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.579867,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Novartis</em> <em>AG</em>, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ABBV34.SA",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.03549,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>AbbVie</em> <em>Inc</em>., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LILY34.SA",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.819199,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Boehringer Ingelheim, AstraZeneca plc, <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "N1VS34.SA",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.57996,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Novartis</em> <em>AG</em>, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "B1SX34.SA",
"name": "Boston Scientific Corporation",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.008814,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Bristol-Myers Squibb, Gerresheimer AG, <em>Boston</em> <em>Scientific</em> <em>Corporation</em>. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CHRS",
"name": "Coherus BioSciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 21.70261,
"sentiment_score": 0.8579,
"highlights": [
{
"highlight": "For instance on 28th February 2024, LTS LOHMANN Therapie-Systeme AG (\"LTS\"), a prominent player in pharmaceutical technology, announced that its client, <em>Coherus</em> <em>BioSciences</em>, <em>Inc</em> (\"Coherus\"), launched UDENYCA® on-body injector (OBI) utilizing the cutting-edge LTS Sorrel™ wearable drug delivery platform.",
"sentiment": 0.8579,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DJNJ2.BA",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.985779,
"sentiment_score": 0.1779,
"highlights": [
{
"highlight": "Competitive Landscape\n\nThe major players operating in the drug delivery technologies market are <em>Johnson</em> & <em>Johnson</em> Services, Inc., Novartis AG, F.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DJNJ3.BA",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.985779,
"sentiment_score": 0.1779,
"highlights": [
{
"highlight": "Competitive Landscape\n\nThe major players operating in the drug delivery technologies market are <em>Johnson</em> & <em>Johnson</em> Services, Inc., Novartis AG, F.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFED.BA",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 8.925057,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Pfizer</em> <em>Inc</em>., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMGN.BA",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.165968,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Sanofi, <em>Amgen</em> <em>Inc</em>., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.BA",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.81882,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Boehringer Ingelheim, AstraZeneca plc, <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVSD.BA",
"name": "NOVARTIS AG",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 11.579985,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Novartis</em> <em>AG</em>, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ABBV.BA",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 11.032904,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>AbbVie</em> <em>Inc</em>., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRKD.BA",
"name": "MERCK & CO INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 13.92888,
"sentiment_score": 0.3548,
"highlights": [
{
"highlight": "., Bayer AG, BD, GSK plc, <em>Merck</em> & <em>Co</em>., <em>Inc</em>., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On 20th September 2023, <em>Merck</em> announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BAYN.BA",
"name": "BAYER AG",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 12.18751,
"sentiment_score": 0.35015,
"highlights": [
{
"highlight": "., <em>Bayer</em> <em>AG</em>, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Recent Developments\n\nOn 23rd November 2023, <em>Bayer</em> invested ~US$136 million in new production facility for innovative parenteral products. The facility features state-of-the-art technology, innovative production, and automated processes.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ABBVD.BA",
"name": "ABBVIE INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 11.032904,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>AbbVie</em> <em>Inc</em>., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILDD.BA",
"name": "GILEAD SCIENCES",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 15.352654,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Gilead</em> <em>Sciences</em>, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 8.924871,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Pfizer</em> <em>Inc</em>., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.928584,
"sentiment_score": 0.3548,
"highlights": [
{
"highlight": "., Bayer AG, BD, GSK plc, <em>Merck</em> & <em>Co</em>., <em>Inc</em>., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On 20th September 2023, <em>Merck</em> announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE.SN",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.924871,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Pfizer</em> <em>Inc</em>., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GXI.DE",
"name": "Gerresheimer AG",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.323507,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Bristol-Myers Squibb, <em>Gerresheimer</em> <em>AG</em>, Boston Scientific Corporation. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.030394,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Boehringer Ingelheim, <em>AstraZeneca</em> <em>plc</em>, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "4AB.DE",
"name": "AbbVie Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.037077,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>AbbVie</em> <em>Inc</em>., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE.DE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.924773,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Pfizer</em> <em>Inc</em>., Bayer AG, BD, GSK plc, Merck & Co., Inc., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.028675,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., <em>Gilead</em> <em>Sciences</em>, <em>Inc</em>., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "6MK.DE",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.927639,
"sentiment_score": 0.3548,
"highlights": [
{
"highlight": "., Bayer AG, BD, GSK plc, <em>Merck</em> & <em>Co</em>., <em>Inc</em>., Sanofi, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On 20th September 2023, <em>Merck</em> announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.DE",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 17.818775,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Boehringer Ingelheim, AstraZeneca plc, <em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMG.DE",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.164546,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Sanofi, <em>Amgen</em> <em>Inc</em>., AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb, Gerresheimer AG, Boston Scientific Corporation.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "9be3058d-3b7c-4c5e-96f5-455e3163d42e",
"title": "Denmark stocks higher at close of trade; OMX Copenhagen 20 up 2.27% By Investing.com",
"description": "Denmark stocks higher at close of trade; OMX Copenhagen 20 up 2.27%",
"keywords": "",
"snippet": "Investing.com – Denmark stocks were higher after the close on Friday, as gains in the , and sectors led shares higher.\n\nAt the close in Copenhagen, the rose 2...",
"url": "https://www.investing.com/news/stock-market-news/denmark-stocks-higher-at-close-of-trade-omx-copenhagen-20-up-227-3401226",
"image_url": "https://i-invdn-com.investing.com/news/LYNXNPEB66095_L.jpg",
"language": "en",
"published_at": "2024-04-26T15:31:49.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "CLPBF",
"name": "Coloplast A/S",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.967,
"sentiment_score": -0.6249,
"highlights": [
{
"highlight": "The worst performers of the session were <em>Coloplast</em> <em>A</em>/<em>S</em> (CSE: ), which fell 0.09% or 0.80 points to trade at 863.40 at the close. Jyske Bank A/S (CSE: ) unchanged 0.00% or 0.00 points to end at 561.50 and Danske Bank A/S (CSE: ) was up 0.10% or 0.20 points to 202.80.",
"sentiment": -0.6249,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CBHD.DE",
"name": "Coloplast A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.95336,
"sentiment_score": -0.6249,
"highlights": [
{
"highlight": "The worst performers of the session were <em>Coloplast</em> <em>A</em>/<em>S</em> (CSE: ), which fell 0.09% or 0.80 points to trade at 863.40 at the close. Jyske Bank A/S (CSE: ) unchanged 0.00% or 0.00 points to end at 561.50 and Danske Bank A/S (CSE: ) was up 0.10% or 0.20 points to 202.80.",
"sentiment": -0.6249,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "0fda5d11-606d-40c6-a8ef-b37f0ab53b7d",
"title": "Full Year 2023 Santhera Pharmaceuticals Holding AG Earnings Call Transcript",
"description": "Apr 25, 2024 / 12:30PM GMTOperator Ladies and gentlemen, welcome to the Santera Pharmaceuticals 2023 financial results and corporate update conference call. I a",
"keywords": "GuruFocus, Article, News, GuruFocus Research, OTCPK:SPHDF",
"snippet": "Apr 25, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nLadies and gentlemen, welcome to the Santera Pharmaceuticals 2023 financial results and corporate update conference call...",
"url": "https://www.gurufocus.com/news/2419725/full-year-2023-santhera-pharmaceuticals-holding-ag-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-04-26T15:15:25.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "SPHDF",
"name": "Santhera Pharmaceuticals Holding AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 207.1094,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Full Year 2023 <em>Santhera</em> <em>Pharmaceuticals</em> <em>Holding</em> <em>AG</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "0c74844e-9e1b-429e-aa77-ddf73cbb7212",
"title": "Q1 2024 Indivior PLC Earnings Call Transcript",
"description": "Apr 25, 2024 / 12:00PM GMTJason Thompson - Indivior PLC - Vice President Investor Relations Good morning, everyone. Before we begin, I need to remind everyone t",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NAS:INDV",
"snippet": "Apr 25, 2024 / 12:00PM GMT\n\nJason Thompson - Indivior PLC - Vice President Investor Relations\n\n\n\nGood morning, everyone. Before we begin, I need to remind every...",
"url": "https://www.gurufocus.com/news/2419724/q1-2024-indivior-plc-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-04-26T15:14:36.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "INVVY",
"name": "Indivior PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 117.89752,
"sentiment_score": 0.242533,
"highlights": [
{
"highlight": "Apr 25, 2024 / 12:00PM GMT\n\nJason Thompson - <em>Indivior</em> <em>PLC</em> - Vice President Investor Relations\n\n\n\nGood morning, everyone. Before we begin, I need to remind everyone that on today's call, we may make forward-looking statements that are subject to risks and uncertainties and that actual results may differ materially.",
"sentiment": -0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Mark Crossley - <em>Indivior</em> <em>PLC</em> - Chief Executive Officer, Executive Director\n\n\n\nThank you, Jason, and good morning and good afternoon, everyone, and thanks for joining us at our first-quarter results call today. Here with me are Ryan Preblick, our Chief Financial Officer; and Christian Heidbreder, our Chief Scientific Officer.",
"sentiment": 0.8807,
"highlighted_in": "main_text"
},
{
"highlight": "Q1 2024 <em>Indivior</em> <em>PLC</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "IZQVF",
"name": "Indivior PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 117.86833,
"sentiment_score": 0.242533,
"highlights": [
{
"highlight": "Apr 25, 2024 / 12:00PM GMT\n\nJason Thompson - <em>Indivior</em> <em>PLC</em> - Vice President Investor Relations\n\n\n\nGood morning, everyone. Before we begin, I need to remind everyone that on today's call, we may make forward-looking statements that are subject to risks and uncertainties and that actual results may differ materially.",
"sentiment": -0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Mark Crossley - <em>Indivior</em> <em>PLC</em> - Chief Executive Officer, Executive Director\n\n\n\nThank you, Jason, and good morning and good afternoon, everyone, and thanks for joining us at our first-quarter results call today. Here with me are Ryan Preblick, our Chief Financial Officer; and Christian Heidbreder, our Chief Scientific Officer.",
"sentiment": 0.8807,
"highlighted_in": "main_text"
},
{
"highlight": "Q1 2024 <em>Indivior</em> <em>PLC</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "f370e3c4-516a-40b6-9b41-10b897f79b2c",
"title": "APTE BIOS : Material Agreement",
"description": "Item 1.01.\n \n \n Entry into a Material Definitive Agreement.\n \n \n \n \n \n On April 24, 2024, Aptose Biosciences Inc. entered...",
"keywords": "Markets",
"snippet": "Item 1.01. Entry into a Material Definitive Agreement.\n\nOn April 24, 2024, Aptose Biosciences Inc. (the \"Company\") entered into an Amended and Restated Warrant ...",
"url": "https://www.marketscreener.com/quote/stock/APTOSE-BIOSCIENCES-INC-1410675/news/APTE-BIOS-Material-Agreement-Form-8-K-46548980/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-04-26T15:07:42.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "APTO",
"name": "Aptose Biosciences Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 62.143486,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "On April 24, 2024, <em>Aptose</em> <em>Biosciences</em> <em>Inc</em>. (the \"Company\") entered into an Amended and Restated Warrant to Purchase Common Shares (the \"Amended Warrant Agreement\") with Hanmi Pharmaceutical Co., Ltd. (\"Hanmi\") in order to comply with Listing Rule 5635 of The Nasdaq Stock Market LLC (\"Nasdaq\").",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "APS.TO",
"name": "Aptose Biosciences Inc.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 54.288155,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "On April 24, 2024, <em>Aptose</em> <em>Biosciences</em> <em>Inc</em>. (the \"Company\") entered into an Amended and Restated Warrant to Purchase Common Shares (the \"Amended Warrant Agreement\") with Hanmi Pharmaceutical Co., Ltd. (\"Hanmi\") in order to comply with Listing Rule 5635 of The Nasdaq Stock Market LLC (\"Nasdaq\").",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "9d1ef1c4-beb3-44dc-9140-0f30353e0088",
"title": "SANUWAVE Health : Material Agreement",
"description": "Item 1.01.\n \n \n \n Entry into a Material Definitive Agreement.\n \n \n \n \n \n \n...",
"keywords": "Markets",
"snippet": "Item 1.01. Entry into a Material Definitive Agreement.\n\n\n\n\n\nOn April 25, 2024, Sanuwave Health, Inc., a Nevada corporation (\"the Company\"), and SEP Acquisition ...",
"url": "https://www.marketscreener.com/quote/stock/SANUWAVE-HEALTH-INC-120791902/news/SANUWAVE-Health-Material-Agreement-Form-8-K-46548979/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-04-26T15:07:42.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "SNWV",
"name": "SANUWAVE Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 96.74875,
"sentiment_score": 0.58735,
"highlights": [
{
"highlight": "On April 25, 2024, <em>Sanuwave</em> <em>Health</em>, <em>Inc</em>., a Nevada corporation (\"the Company\"), and SEP Acquisition Corp., a Delaware corporation (\"SEPA\"), entered into that certain Amendment Number Two (the \"Amendment\") to the Agreement and Plan of Merger, dated as of August 23, 2023, by and among the Company, SEPA and SEP Acquisition Holdings Inc., a Nevada corporation",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>SANUWAVE</em> <em>Health</em> : Material Agreement",
"sentiment": 0.4939,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "94e183af-1fb7-4e2b-acf9-9021182aa390",
"title": "PAVmed : Material Agreement",
"description": "Item 1.01. Entry into a Material Definitive Agreement.\n \n \n \n On April 25, 2024, PAVmed Inc. entered into a letter agreement with the holder of the senior secured convertible...",
"keywords": "Markets",
"snippet": "Item 1.01. Entry into a Material Definitive Agreement.\n\nOn April 25, 2024, PAVmed Inc. (the \"Company\") entered into a letter agreement with the holder of the se...",
"url": "https://www.marketscreener.com/quote/stock/PAVMED-INC-30353188/news/PAVmed-Material-Agreement-Form-8-K-46548971/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-04-26T15:07:40.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "PAVM",
"name": "PAVmed Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 78.95909,
"sentiment_score": 0.24695,
"highlights": [
{
"highlight": "On April 25, 2024, <em>PAVmed</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>PAVmed</em> : Material Agreement",
"sentiment": 0.4939,
"highlighted_in": "title"
}
]
},
{
"symbol": "PAVMW",
"name": "PAVmed Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 78.92367,
"sentiment_score": 0.24695,
"highlights": [
{
"highlight": "On April 25, 2024, <em>PAVmed</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>PAVmed</em> : Material Agreement",
"sentiment": 0.4939,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "294e5663-35e4-409b-b54c-50ed22439f23",
"title": "Delcath : Material Agreement",
"description": "Item 1.01\n \n \n \n Entry into a Material Definitive Agreement.\n \n \n \n \n \n ...",
"keywords": "Markets",
"snippet": "Item 1.01 Entry into a Material Definitive Agreement.\n\nOn April 22, 2024, Delcath Systems, Inc. (\"Delcath\") entered into a Fifth Amendment, effective May 1, 202...",
"url": "https://www.marketscreener.com/quote/stock/DELCATH-SYSTEMS-INC-43232097/news/Delcath-Material-Agreement-Form-8-K-46548939/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-04-26T15:07:35.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "DCTH",
"name": "Delcath Systems, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.62632,
"sentiment_score": 0,
"highlights": [
{
"highlight": "On April 22, 2024, <em>Delcath</em> <em>Systems</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "2a21950f-ced4-468d-8225-949a0e6629c2",
"title": "Annovis Bio : Material Agreement",
"description": "Item 1.01 Entry into a Material Definitive Agreement.\n \n \n \n On April 25, 2024, Annovis Bio, Inc., a Delaware corporation , entered into a Common Stock Purchase Agreement with...",
"keywords": "Markets",
"snippet": "Item 1.01 Entry into a Material Definitive Agreement.\n\nOn April 25, 2024, Annovis Bio, Inc., a Delaware corporation (the \"Company\"), entered into a Common Stock...",
"url": "https://www.marketscreener.com/quote/stock/ANNOVIS-BIO-INC-102588345/news/Annovis-Bio-Material-Agreement-Form-8-K-46548944/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-04-26T15:07:35.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "ANVS",
"name": "Annovis Bio, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.744774,
"sentiment_score": 0.57125,
"highlights": [
{
"highlight": "On April 25, 2024, <em>Annovis</em> <em>Bio</em>, <em>Inc</em>., a Delaware corporation (the \"Company\"), entered into a Common Stock Purchase Agreement (the \"Purchase Agreement\") with the Equity Line investor (the \"ELOC Purchaser\"), whereby the Company may offer and sell, from time to time at its sole discretion, and whereby the ELOC Purchaser has committed to purchase, up to",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Annovis</em> <em>Bio</em> : Material Agreement",
"sentiment": 0.4939,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "7935c765-017c-4aff-bbce-be62773fd4bd",
"title": "Deutsche Dividenden-Aktien: Das sind 2024 die Stars in DAX, MDAX und SDAX",
"description": "Dividendenstudie 2024 - DAX: außer Dividenden nichts gewesen - Deutsche Aktien im Dividendencheck - Qualität, Wachstum und Dividende vereinen",
"keywords": "",
"snippet": "Deutschlands bekannter Dividendenexperte Christian W. Röhl (dividendenadel.de) hat in Zusammenarbeit mit dem Institut for Strategic Finance der FOM Hochschule ...",
"url": "https://www.ftd.de/finanzen/aktien-und-maerkte/deutsche-dividenden-aktien-das-sind-2024-die-stars-in-dax-mdax-und-sdax/",
"image_url": "https://www.ftd.de/wp-content/uploads/Das-sind-die-deutschen-Dividendenstars-1000x600.jpg",
"language": "de",
"published_at": "2024-04-26T15:04:26.000000Z",
"source": "ftd.de",
"relevance_score": null,
"entities": [
{
"symbol": "NXU.DE",
"name": "Nexus AG",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 16.755627,
"sentiment_score": null,
"highlights": [
{
"highlight": "Im Nebenwerte-Bereich erfüllen der Tiefkühlkost-Hersteller Frosta, der innovative Medizinsoftwarehersteller <em>Nexus</em> <em>AG</em> und der Software-CAD-Spezialist Mensch und Maschine diese Parameter. Alle 3 genannten Unternehmen können zudem mit einer positiv geprägten, gründergeführten Unternehmenskultur punkten.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Healthcare",
"total_documents": 819,
"sentiment_avg": 0.26171012649102315
}
]
}
Other details
Entity count
- 11,442